Metastatic Breast Cancer Clinical Trials

71 studies are recruiting for metastatic breast cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 3

1. A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

   The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   12 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06099769 on ClinicalTrials.gov

2. A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

   The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT04683679 on ClinicalTrials.gov

3. Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

   This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama Birmingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   Sonya Reid

   See if you can join NCT05693766 on ClinicalTrials.gov

4. Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise

   This study will examine unmet exercise needs among patients with metastatic breast cancer (MBC) at UNC and assess whether participation in Get Real and Heel (GRH) can increase physical activity. The proposed research aims to improve multiple domains of well-being, quality of life, physical function…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07313306 on ClinicalTrials.gov

5. Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

   This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.

   Stage

   Phase 2

   Ages

   60 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Run by

   University of Alabama at Birmingham

   See if you can join NCT06105684 on ClinicalTrials.gov

6. Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

   Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical trials in patients with metastatic triple negative breast cancer (mTNBC) and hormone receptor positive/HER2 negative (HR+/HER2-) metastatic br…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT06774027 on ClinicalTrials.gov

7. BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

   This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with HR positive, HER-2 negative metastatic or unresectable breast cancer. Patients will receive f…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT05977036 on ClinicalTrials.gov

8. Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

   The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06409390 on ClinicalTrials.gov

9. Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

   Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dartmouth Cancer Center, Lebanon, New Hampshire

   Run by

   Mary D Chamberlin

   See if you can join NCT05900895 on ClinicalTrials.gov

10. Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer

    Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not always happen as early or as often as patients and families would like. This multi-site study will t…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT06795529 on ClinicalTrials.gov

11. Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer

    Black and Latina women experience disparities in supportive and palliative care access and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and acceptability of a community navigator delivered supportive care intervention for historically underserved populations of wome…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mount Sinai Hospital, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06405828 on ClinicalTrials.gov

12. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer age…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Sarasota, Florida

    Locations

    8 in total

    Run by

    Olema Pharmaceuticals, Inc.

    See if you can join NCT06784193 on ClinicalTrials.gov

13. The COMPASSION Study

    The aim of this research study is to better understand the in-home hospice experience for participants, caregivers, hospice nurses, and oncology providers by conducting telehealth check-ins between participants and caregivers and oncology care teams.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06507930 on ClinicalTrials.gov

14. Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians

    I this qualitative study, Investigators will conduct semi-structured interviews with clinicians that are involved in the care of patients with breast cancer to evaluate the acceptability, appropriateness, and feasibility/usability of a metastatic breast cancer-specific prognostic tool. These interv…

    Stage

    Not phased

    Ages

    Any age

    Site

    University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05440929 on ClinicalTrials.gov

15. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Arizona Cancer Center, Tucson, Arizona

    Locations

    37 in total

    Run by

    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

16. Definitive Radiation for High-Risk Spine Metastases

    This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stony Brook University Hospital, Stony Brook, New York

    Run by

    Stony Brook University

    See if you can join NCT06165419 on ClinicalTrials.gov

17. Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

    This multi-site study is being conducted to examine dietary and activity patterns, body composition, blood and quality of life in breast cancer patients. The study will recruit 176 women with MBC in Milwaukee (n=88) and Chicago (n=88).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Loyola University, Maywood, Illinois

    Locations

    2 in total

    Run by

    Medical College of Wisconsin

    See if you can join NCT03824145 on ClinicalTrials.gov

18. Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

    This is a phase 2, open-label, single-arm trial designed to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in combination with pembrolizumab following disease progression after two prior lines of standard therapy in unresectable metastatic stage IV breast cancer

    Stage

    Phase 2

    Ages

    18 and older

    Site

    James Graham Brown Cancer Center, Louisville, Kentucky

    Run by

    University of Louisville

    See if you can join NCT04990921 on ClinicalTrials.gov

19. A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

    This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study wil…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Florida Cancer Specialists, Lake Mary, Florida

    Locations

    6 in total

    Run by

    Edgewood Oncology Inc.

    See if you can join NCT04872166 on ClinicalTrials.gov

20. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

21. Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

    Phase I/II study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1*).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    Minerva Biotechnologies Corporation

    See if you can join NCT04020575 on ClinicalTrials.gov